Pulmonary and Critical Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Am J Respir Crit Care Med. 2012 Jul 15;186(2):155-61. doi: 10.1164/rccm.201201-0034OC. Epub 2012 May 3.
Patients with chronic obstructive pulmonary disease (COPD) are afflicted by comorbidities. Few studies have prospectively evaluated COPD comorbidities and mortality risk.
To prospectively evaluate COPD comorbidities and mortality risk.
We followed 1,664 patients with COPD in five centers for a median of 51 months. Systematically, 79 comorbidities were recorded. We calculated mortality risk using Cox proportional hazard, and developed a graphic representation of the prevalence and strength of association to mortality in the form of a "comorbidome". A COPD comorbidity index (COPD specific comorbidity test [COTE]) was constructed based on the comorbidities that increase mortality risk using a multivariate analysis. We tested the COTE index as predictor of mortality and explored whether the COTE index added predictive information when used with the validated BODE index.
Fifteen of 79 comorbidities differed in prevalence between survivors and nonsurvivors. Of those, 12 predicted mortality and were integrated into the COTE index. Increases in the COTE index were associated with an increased risk of death from COPD-related (hazard ratio [HR], 1.13; 95% confidence interval, 1.08-1.18; P < 0.001) and non-COPD-related causes (HR, 1.18; 95% confidence interval, 1.15-1.21; P < 0.001). Further, increases in the BODE and COTE were independently associated with increased risk of death. A COTE score of greater than or equal to 4 points increased by 2.2-fold the risk of death (HR, 2.26-2.68; P < 0.001) in all BODE quartile.
Comorbidities are frequent in COPD and 12 of them negatively influence survival. A simple disease-specific comorbidities index (COTE) helps assess mortality risk in patients with COPD.
慢性阻塞性肺疾病(COPD)患者常合并多种疾病。很少有研究前瞻性评估 COPD 合并症与死亡风险。
前瞻性评估 COPD 合并症与死亡风险。
我们在 5 个中心对 1664 例 COPD 患者进行了中位时间为 51 个月的随访。系统记录了 79 种合并症。我们使用 Cox 比例风险模型计算死亡率风险,并以“合并症组”的形式构建一种图形表示方法来展示与死亡率相关的合并症的患病率和关联强度。基于增加死亡风险的合并症,使用多变量分析构建了 COPD 合并症指数(COPD 特异性合并症测试[COTE])。我们检验了 COTE 指数作为死亡率预测因子的作用,并探讨了在使用经过验证的 BODE 指数的情况下,COTE 指数是否增加了预测信息。
79 种合并症中,15 种在幸存者和非幸存者之间的患病率不同。其中,12 种预测了死亡,并被纳入 COTE 指数。COTE 指数的增加与 COPD 相关(风险比[HR],1.13;95%置信区间,1.08-1.18;P < 0.001)和非 COPD 相关原因(HR,1.18;95%置信区间,1.15-1.21;P < 0.001)死亡风险的增加相关。此外,BODE 和 COTE 的增加与死亡风险的增加独立相关。COTE 评分大于或等于 4 分使所有 BODE 四分位数的死亡风险增加 2.2 倍(HR,2.26-2.68;P < 0.001)。
COPD 患者常合并多种疾病,其中 12 种疾病对生存有负面影响。一种简单的疾病特异性合并症指数(COTE)有助于评估 COPD 患者的死亡风险。